BIO 2021 Notebook: Biogen CEO On Corporate Responsibility

17 Jun 2021

• By Scrip Team and Pink Sheet Team

News and views from day four of the BIO Digital annual meeting include the FDA's plans to use carrots not sticks to improve diversity and reflections on how the pandemic has strengthened biopharmaceutical supply chains.

Biogen, Inc. has gotten a lot of criticism about the $56,000-a-year price tag for its new Alzheimer's drug Aduhelm (aducanumab), given that it was granted an accelerated approval by the US Food and Drug Administration based on a surrogate endpoint and the efficacy still needs to be confirmed. Speaking about corporate responsibility at the Biotechnology Innovation Organization (BIO) annual meeting with BIO CEO Michelle McMurry-Heath on 17 June, CEO Michel Vountasos said the company has to do a better job communicating its position to the public.

"The company is taking a position that is very responsible that is yet to be understood out there, and we...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

ASCO: Pushing The Frontiers Of ADCs

19 Jun 2025

• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.